Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJCIGN)

• Drug Name: CC-95775 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMJCIGN

Molecule-Related Drug Atlas

Drug(s) Targeting Bromodomain and extraterminal domain protein (BET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CPI-0610	DMPXOYJ	Myelofibrosis	2A20.2	Phase 3	[3]
ZEN-3694	DM6VQTF	Prostate cancer	2C82.0	Phase 2	[4]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
BMS-986158	DM6LDI4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
INCB054329	DM7TZL0	Refractory hematologic malignancy	2A85.5	Phase 1/2	[5]
INCB057643	DMG65CV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
ODM-207	DMOKVJD	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[8]
GSK525762	DMPAWBN	Haematological malignancy	2B33.Y	Phase 1	[3]
PLX51107	DMXLHVW	Haematological malignancy	2B33.Y	Phase 1	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain and extraterminal domain protein (BET)	TTE4BSY	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04089527) Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of Zenith Epigenetics.
• [5] The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
• [6] Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
• [7] First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)